Comparing the current results to its competitors, Oncotelic Therapeutics Inc reported Revenue increase in the 2 quarter 2026 by 0 % year on year. The revenue growth was below Oncotelic Therapeutics Inc 's competitors' average revenue growth of 59.04 %, achieved in the same quarter.
Oncotelic Therapeutics Inc 's Comment on Competition and Industry Peers
The industry is marked by ongoing product development and intense competition. Competitors include major pharmaceutical, biopharmaceutical, and biotechnology companies, many possessing substantially greater financial, technical, and marketing resources. Smaller companies frequently collaborate with larger, established firms to support research, development, and commercialization of potential products. Academic institutions, governmental agencies, and other public and private research organizations also engage in research and patent new technologies that may compete. Competition is based on factors such as product efficacy, safety, patient convenience, reliability, price, patent protection, the ability to attract and retain qualified personnel, and the development of effective products.
Publicly Traded Peers of Oncotelic Therapeutics Inc
Ascendis Pharma A Share Performance
+31.42%
One Year
Ascendis Pharma A
Profile
Ascendis Pharma is a pharmaceutical company that focuses on developing innovative therapies for rare diseases using its proprietary TransCon technology platform. They aim to improve patient outcomes by providing long-acting, once-weekly or once-monthly treatments. With a focus on rare endocrine diseases, they aim to address the unmet medical needs of patients through their unique approach to drug development.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
International Stem Cell Corporation Share Performance
+153.57%
One Year
International Stem Cell Corporation
Profile
International Stem Cell Corporation is a biotechnology company that focuses on developing and commercializing stem cell-based therapeutic products. They utilize their unique technology to derive unlimited amounts of pluripotent stem cells, enabling them to create therapeutics for various medical conditions.
Kezar Life Sciences Inc is a biotechnology company that focuses on developing novel small molecule therapeutics. Their business model revolves around the discovery and development of innovative drugs to target autoimmune and inflammatory disorders, aiming to address unmet medical needs. They primarily operate by conducting extensive research and conducting clinical trials to deliver effective treatments for patients.
Sources:
Oncotelic Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Oncotelic Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
